Transactions
8
Insider / SUPERNUS PHARMACEUTICALS, INC.
NEWHALL CHARLES W III
Director at SUPERNUS PHARMACEUTICALS, INC.
- Ticker
- SUPN
- First filing on record
- October 10, 2025
- Latest trade on record
- February 24, 2026
- SEC filings
- EDGAR ↗
NEWHALL CHARLES W III, Director at SUPERNUS PHARMACEUTICALS, INC., has disclosed 8 transactions in SUPN since October 10, 2025: 0 purchases (0 open-market buys) and 2 sales, worth about $1.5M at the reported prices. The latest was filed February 25, 2026, 1 day after the trade.
Open-market buys
0
Sales
2
Avg. disclosure lag
1.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months NEWHALL CHARLES W III reported 6 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
NEWHALL CHARLES W III has traded 1 stock on record; the largest by dollars is SUPN.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 3 | 12,441 | — |
| M | Option exercise or conversion | 2 | 30,000 | $195K |
| S | Open-market sale | 2 | 25,000 | $1.3M |
| D | Sale back to the company | 1 | 4,475 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 4 | 0 | 0 |
| 2025 | 4 | 0 | 2 · $1.3M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN | Option / conversion D | February 24, 2026 | February 25, 2026 | 1d | 4,475 | — | — | derivative | Form 4 ↗ | |
| SUPN | Other A | February 24, 2026 | February 25, 2026 | 1d | 4,475 | — | — | Form 4 ↗ | ||
| SUPN | Other A | February 18, 2026 | February 20, 2026 | 2d | 4,977 | — | — | derivative | Form 4 ↗ | |
| SUPN | Other A | February 18, 2026 | February 20, 2026 | 2d | 2,989 | — | — | derivative | Form 4 ↗ | |
| SUPN | Option / conversion M | November 21, 2025 | November 24, 2025 | 3d | 15,000 | — | — | derivative | Form 4 ↗ | |
| SUPN | Option / conversion M | November 21, 2025 | November 24, 2025 | 3d | 15,000 | $13 | $195K | Form 4 ↗ | ||
| SUPN | Sell S | October 9, 2025 | October 10, 2025 | 1d | 1,200 | $52 | $62K | 10b5-1 plan | Form 4 ↗ | |
| SUPN | Sell S | October 9, 2025 | October 10, 2025 | 1d | 23,800 | $51 | $1.2M | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| February 25, 2026 | Form 4 | 0001005544-26-000004 | 2 | published | EDGAR ↗ |
| February 20, 2026 | Form 4 | 0001005544-26-000002 | 2 | published | EDGAR ↗ |
| November 24, 2025 | Form 4 | 0001628280-25-053877 | 2 | published | EDGAR ↗ |
| October 10, 2025 | Form 4 | 0001628280-25-044797 | 2 | published | EDGAR ↗ |
Other insiders at SUPERNUS PHARMACEUTICALS, INC.
- Bhatt Padmanabh P. Sr. VP of IP, CSO 44 rows
- Khattar Jack A. President, CEO 33 rows
- Mottola Frank SVP, Chief Tech. Ops. Officer 29 rows
- DEC TIMOTHY C Senior Vice-President & CFO 26 rows
- Rubin Jonathan SVP, Chief Medical Officer 18 rows
- Horich William Todd SVP, Commercial Operations 11 rows
- GEMAYEL GEORGES Director 10 rows
- Hudson Frederick M. Director 7 rows
- Sensenig Bethany Director 6 rows
- Barlow Carrolee Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: SUPERNUS PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 8 | October 10, 2025 | February 25, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.